We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Teaching neurons to respond to placebos as potential treatment for Parkinson’s
News

Teaching neurons to respond to placebos as potential treatment for Parkinson’s

Teaching neurons to respond to placebos as potential treatment for Parkinson’s
News

Teaching neurons to respond to placebos as potential treatment for Parkinson’s

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Teaching neurons to respond to placebos as potential treatment for Parkinson’s"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Scientist have discovered a way to make neurons respond to a placebo (a medically ineffective treatment), in the same way as they would to medically effective treatment, according to a study published in The Journal of Physiology.


They found that it is possible to turn a neuron which previously hasn’t responded to placebos (placebo ‘non-responder’ neuron) into a placebo ‘responder’ by conditioning Parkinson patients with apomorphine, a dopaminergic drug used in the treatment of Parkinson's disease (PD). 


See Also: New lead for potential Parkinson’s treatment


When a placebo (saline solution) was given for the first time, it induced neither clinical benefit nor associated neuronal changes in the thalamus, a brain region known to be involved in PD. However, if repeated administrations of apomorphine were performed before placebo administration, a placebo was capable of increasing thalamus neuronal activity along with clinical improvement (reduction of muscle rigidity).


Interestingly, the higher the previous administrations of apomorphine was, the larger the neuronal changes and the clinical improvement. When apomorphine was administered for 4 days in a row, the subsequent administration of a placebo induced a response that was as large as the one induced by apomorphine. These changes lasted for 24 hours.


The researchers administered apomorphine, either 1, 2, 3 or 4 days before the surgical implantation of electrodes for deep brain stimulation, which is an effective treatment for PD. During surgery, they replaced apomorphine with a placebo and recorded from single neurons in the thalamus along with the assessment of muscle rigidity of the arm.


Fabrizio Benedetti, from the Department of Neuroscience at University of Turin Medical School, Italy and first author of the study, explained,


Learn More: Study Confirms Parkinson's Enhances Creativity


‘These findings show that is possible to teach neurons in the thalamus to respond to placebos, so that a placebo non-responder can be turned into a placebo responder. These findings may have profound implications and applications, because we can reduce drug intake by exploiting these learning mechanisms. Since this study shows that there is a memory for drug action, the alternate administration drug-placebo-drug- placebo etc. means people would need to take less medication but yet obtain the same clinical benefit.


‘If a placebo is given after four previous administrations of apomorphine, the placebo response can be as large as the drug response, and this effect lasts up to 24 hours. Therefore, a future challenge will be to see whether this effect can be extended beyond 24 hours.’


Note: Material may have been edited for length and content. For further information, please contact the cited source.

The Physiological Society   press release


Publication

Benedetti F et al. Teaching neurons to respond to placebos.  The Journal of Physiology, Published Online February 9 2016. doi: 10.1113/JP271322


Advertisement